




# Impact of *UGT1A1* genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer

Satoru Iwasa<sup>1</sup>  | Kei Muro<sup>2</sup> | Satoshi Morita<sup>3</sup> | Young Suk Park<sup>4</sup> | Masato Nakamura<sup>5</sup> | Masahito Kotaka<sup>6</sup> | Tomohiro Nishina<sup>7</sup> | Hiroshi Matsuoka<sup>8</sup> | Joong Bae Ahn<sup>9</sup> | Keun-Wook Lee<sup>10</sup> | Yong Sang Hong<sup>11</sup> | Sae Won Han<sup>12</sup> | Sang-Hee Cho<sup>13</sup>  | Dong-Sheng Zhang<sup>14</sup> | Wei-Jia Fang<sup>15</sup>  | Li Bai<sup>16</sup> | Xiang-Lin Yuan<sup>17</sup> | Ying Yuan<sup>18</sup> | Yasuhide Yamada<sup>19,20</sup> | Junichi Sakamoto<sup>21</sup> | Tae Won Kim<sup>11</sup>

<sup>1</sup>Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

<sup>2</sup>Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

<sup>3</sup>Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>4</sup>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

<sup>5</sup>Department of Chemotherapy, Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan

<sup>6</sup>Department of Digestive Surgery, Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan

<sup>7</sup>Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

<sup>8</sup>Department of General Gastroenterological Surgery, Fujita Health University Hospital, Toyoake, Japan

<sup>9</sup>Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

<sup>10</sup>Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

<sup>11</sup>Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea

<sup>12</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

<sup>13</sup>Department of Hematology-Oncology, Chonnam National University Hospital, Medical School, Gwangju, Korea

<sup>14</sup>Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

<sup>15</sup>Department of Medical Oncology, First Affiliated Hospital, Zhejiang University, Hangzhou, China

<sup>16</sup>Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China

<sup>17</sup>Department of Gastrointestinal Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China

<sup>18</sup>Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

<sup>19</sup>Comprehensive Cancer Center, National Center for Global Health and Medicine, Shizuoka, Japan

<sup>20</sup>Department of Medical Oncology, Hamamatsu University School of Medicine, Shizuoka, Japan

<sup>21</sup>Tokai Central Hospital, Kakamigahara, Japan

**Abbreviations:** AE, adverse event; AXEPT, Asian XELIRI Project; CI, confidence interval; DHH, double heterozygous or homozygous; FOLFIRI, fluorouracil plus leucovorin with irinotecan; HR, hazard ratio; mCRC, metastatic colorectal cancer; mXELIRI, modified capecitabine plus irinotecan; OS, overall survival; PFS, progression-free survival; SH, single heterozygous.

Satoru Iwasa and Kei Muro contributed equally to this work. Trial registration: ClinicalTrials.gov Identifier: NCT01996306, and UMIN Clinical Trials Registry Identifier: UMIN000012263.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *Cancer Science* published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

**Correspondence**

Tae Won Kim, Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea.  
Email: twkimmd@amc.seoul.kr

**Funding information**

Epidemiological and Clinical Research Information Network; Asan Medical Center Academic Research Office; Sun Yat-sen University Cancer Center; Chugai Pharmaceutical; F Hoffmann-La Roche.

**Abstract**

The phase III AXEPT study showed the noninferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second-line treatment for metastatic colorectal cancer. We evaluated the associations between the *UGT1A1* genotype linked to adverse events—caused by irinotecan—and the efficacy and safety of mXELIRI and FOLFIRI. The *UGT1A1* genotype was prospectively determined and patients were categorized into three groups according to WT (\*1/\*1), single heterozygous (SH; \*28/\*1 or \*6/\*1), and double heterozygous or homozygous (DHH; \*28/\*28, \*6/\*6, or \*28/\*6). Overall survival (OS), progression-free survival, response rate, and safety were assessed. The *UGT1A1* genotype was available in all 650 randomized patients (WT, 309 [47.5%]; SH, 291 [44.8%]; DHH, 50 [7.7%]). The median OS was 15.9, 17.7, and 10.6 months in the WT, SH, and DHH groups, respectively, with an adjusted hazard ratio (HR) of 1.53 (95% confidence interval [CI], 1.12–2.09;  $P = .008$ ) for DHH vs WT or SH. The median OS in the mXELIRI and FOLFIRI arms was 18.1 vs 14.3 months (HR 0.80; 95% CI, 0.62–1.03) in the WT group, 16.3 vs 18.3 months (HR 1.04; 95% CI, 0.79–1.36) in the SH group, and 13.0 vs 9.1 months (HR 0.71; 95% CI, 0.39–1.31) in the DHH group, respectively. Modified capecitabine plus irinotecan with or without bevacizumab could be a standard second-line chemotherapy in terms of efficacy and safety regardless of the *UGT1A1* genotype.

**KEYWORDS**

capecitabine, colorectal cancer, irinotecan, *UGT1A1*, XELIRI

**1 | INTRODUCTION**

The combination of fluorouracil with irinotecan (FOLFIRI) is widely accepted as a standard cytotoxic chemotherapy regimen for mCRC, either as a first- or second-line treatment.<sup>1,2</sup> Additionally, FOLFIRI combined with a molecular targeted agent (ie, bevacizumab, ramucirumab, aflibercept, cetuximab, panitumumab) is commonly selected as a second-line therapeutic option.<sup>3–6</sup>

Irinotecan is converted to its active metabolite (SN-38) by carboxylesterase and glucuronidated to SN-38G by UDP-glucuronosyltransferase encoded by the *UGT1A1* gene. As such, patients who are heterozygous or homozygous for *UGT1A1*\*28 and *UGT1A1*\*6 polymorphisms have reduced ability to form SN-38G and delayed SN-38 metabolism compared with those who do not carry these polymorphisms.<sup>7</sup> The use of irinotecan in patients with such polymorphisms has been associated with the occurrence of more serious AEs such as neutropenia or diarrhea.<sup>8–10</sup> However, the appropriate dose and efficacy of irinotecan for patients homozygous for *UGT1A1*\*28 or \*6, or heterozygous for both *UGT1A1*\*28 and \*6 is yet to be determined. The prescription information for irinotecan as approved by the US FDA states that “when administered in combination with other agents, or as a single-agent, a reduction in the starting dose by at least one level of irinotecan should be considered for patients known to be homozygous for the *UGT1A1*\*28

allele.” Importantly, Toffoli et al suggested an association between *UGT1A1*\*28 homozygosity and greater efficacy, despite more severe toxicity; however, other studies failed to find any significant impact of *UGT1A1* genotypes on survival.<sup>8,11–13</sup> As such, an individualized dose for irinotecan in this patient population has yet to be established by large-scale prospective clinical studies.

Recently, the phase III AXEPT study found the noninferiority of mXELIRI with or without bevacizumab relative to FOLFIRI with or without bevacizumab in terms of OS as a second-line treatment for patients with mCRC.<sup>14</sup> In the AXEPT study, *UGT1A1* genotyping was mandatory at the screening stage. Here, we report the results of a preplanned analysis of the AXEPT study that evaluated the associations between the *UGT1A1* genotype and the safety and efficacy of irinotecan-based regimens.

**2 | MATERIALS AND METHODS****2.1 | Patients**

The detailed eligibility criteria for this study have been previously reported.<sup>14</sup> In brief, patients aged 20 years or older with histologically confirmed mCRC, ECOG performance status of 0–2, adequate organ function, and disease progression or intolerance to

first-line chemotherapy were eligible for enrollment. The study was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and the protocol was reviewed and approved by the institutional review board of each study site prior to the initiation of the study. All patients provided written informed consent.

## 2.2 | Study design and administration of drugs

Patients were centrally randomly assigned at a 1:1 ratio to receive either FOLFIRI with or without bevacizumab or mXELIRI with or without bevacizumab. The FOLFIRI regimen consisted of irinotecan 180 mg/m<sup>2</sup> plus leucovorin 400 mg/m<sup>2</sup> plus fluorouracil 400 mg/m<sup>2</sup> bolus, all on day 1, followed by fluorouracil 2400 mg/m<sup>2</sup> given as a 46-hour continuous infusion with or without bevacizumab 5 mg/kg on day 1, repeated every 2 weeks. The mXELIRI regimen consisted of irinotecan 200 mg/m<sup>2</sup> on day 1, plus capecitabine 800 mg/m<sup>2</sup> twice daily on days 1-14 with or without bevacizumab 7.5 mg/kg on day 1, repeated every 3 weeks. A reduced starting dose of irinotecan of 150 mg/m<sup>2</sup> was given in patients identified as homozygous for *UGT1A1*\*6 or *UGT1A1*\*28 or double heterozygous for both *UGT1A1*\*6 and *UGT1A1*\*28, regardless of the treatment arm. Detailed treatment modifications were as previously described.<sup>14</sup>

## 2.3 | *UGT1A1* genotyping

The *UGT1A1* genotype was determined using the Invader assay (Sekisui Medical Co. Ltd.), the TaqMan assay and PCR direct sequencing (DNA Link, Inc), and the *UGT1A1* Genotype Detection Kit (Shanghai Yuanqi Bio-Pharmaceutical Co. Ltd.). The *UGT1A1*\*28 polymorphism has seven TA repeats in the promoter region (TATA) instead of the six repeats in WT *UGT1A1*; thus, the genotypes were designated as WT (*UGT1A1*\*28 6/6), heterozygous (*UGT1A1*\*28 6/7), and homozygous (*UGT1A1*\*28 7/7). Similarly, the *UGT1A1*\*6 polymorphism involves an amino acid substitution in exon 1 (211G>A); as such, the genotypes were designated as WT (*UGT1A1*\*6 G/G), heterozygous (*UGT1A1*\*6 G/A), and homozygous (*UGT1A1*\*6 A/A). Accordingly, we stratified patients into three groups: WT (*UGT1A1*\*6 G/G or \*28 6/6), SH (*UGT1A1*\*6 G/G and \*28 6/7, or *UGT1A1*\*6 G/A and \*28 6/6), and DHH (*UGT1A1*\*6 G/A and \*28 6/7, *UGT1A1*\*6 A/A, or \*28 7/7).

## 2.4 | End-points and assessments

The end-points of this study were OS, PFS, objective response rate, and safety. Tumor responses were assessed according to the RECIST guideline version 1.1. Overall survival was defined as the time from the date of randomization to death from any cause. Progression-free survival was defined as the time from the date of randomization to disease progression or death from any cause. Adverse events were assessed according to the NCI's Common

Terminology Criteria for Adverse Events version 4.0. Relative dose intensity was calculated as the total dose of each drug actually administered divided by the planned dose during the protocol treatment.

## 2.5 | Statistical analysis

Survival end-points were estimated using the Kaplan-Meier method and compared with log-rank test. The HRs and associated 95% CIs for the comparison of OS and PFS between different *UGT1A1* genotypes were calculated using the Cox proportional hazards models adjusted by country (Japan vs South Korea vs China), ECOG performance status (0-1 vs 2), number of metastatic sites (1 vs >1), previous use of oxaliplatin treatment (yes vs no), and concurrent bevacizumab treatment (with vs without). The objective response rate and incidences of AEs were assessed with the  $\chi^2$  test and Fisher's exact test, respectively. The significance level was set to .05. All statistical analyses were carried out using SAS versions 9.3 and 9.4.


## 3 | RESULTS

### 3.1 | Patients

In total, 650 patients were enrolled between December 2, 2013 and August 13, 2015, and the cut-off for data accrual was July 28, 2017. Nine patients were identified as ineligible after enrolment (five for recurrence more than 6 months after last dose of adjuvant chemotherapy, and one each for use of aspirin for more than 325 mg/d, baseline hemoglobin less than 9.0 g/dL, baseline total bilirubin more than 1.5 mg/dL, and active gastrointestinal bleeding) and 21 patients did not receive any study treatment. The dataset for full analysis used for the efficacy end-point included all 650 patients, of whom 620 received at least one dose on protocol and were included in the safety analysis. The *UGT1A1* genotypes of the patients were as follows: WT (n = 309; 47.5%), SH (n = 291; 44.8%), and DHH (n = 50; 7.7%) (Figure 1); the proportions of patients carrying the different genetic polymorphisms were similar among different countries (Table S1). The baseline demographics and disease characteristics were generally well-balanced among the three groups, with the exception of the higher percentages of patients with right-sided tumors and those without liver metastasis in the DHH group (Tables 1 and S2).

### 3.2 | Treatment efficacies according to *UGT1A1* genotypes

During a median follow-up of 15.8 months (interquartile range, 8.7-24.9 months), the median PFS was 7.1 (95% CI, 6.5-8.3), 8.6 (95% CI, 7.3-9.9), and 5.3 (95% CI, 3.9-9.9) months in the WT, SH, and DHH



**FIGURE 1** Patient flow diagram in the Asian XELIRI Project (AXEPT) study of modified capecitabine plus irinotecan with or without bevacizumab or fluorouracil, leucovorin, and irinotecan with or without bevacizumab as second-line treatment for metastatic colorectal cancer

groups, respectively (Figure 2A). During the same period, the median OS was 15.9 (95% CI, 14.5-18.1), 17.7 (95% CI, 15.5-19.7), and 10.6 (95% CI, 8.0-14.1) months in the WT, SH, and DHH groups, respectively (Figure 2B). The adjusted HR for OS in the DHH group vs WT or SH groups was 1.53 (95% CI, 1.12-2.09;  $P = .008$ ).

### 3.3 | Treatment efficacies in FOLFIRI and mXELIRI arms according to *UGT1A1* genotypes

The median PFS of patients in the mXELIRI and FOLFIRI arms was 8.3 vs 6.8 months (HR 0.88; 95% CI, 0.70-1.12;  $P = .299$ ) in the WT group, 8.7 vs 8.8 months (HR 1.06; 95% CI, 0.83-1.35;  $P = .626$ ) in the SH group, and 6.5 vs 4.8 months (HR 0.73; 95% CI, 0.41-1.32;  $P = .295$ ) in the DHH group (Figure 3A). The median OS in the mXELIRI and FOLFIRI arms was 18.1 vs 14.3 months (HR 0.80; 95% CI, 0.62-1.03;  $P = .077$ ) in the WT group, 16.3 vs 18.3 months (HR 1.04; 95% CI, 0.79-1.36;  $P = .805$ ) in the SH group, and 13.0 vs 9.1 months (HR 0.71; 95% CI, 0.39-1.31;  $P = .271$ ) in the DHH group (Figure 3B). No differences were observed in PFS and OS for each treatment among *UGT1A1\*6* and *UGT1A1\*28* (Figure S1). Among the 620 evaluable patients, the proportion of patients achieving an objective response was lower in the FOLFIRI arm than in the mXELIRI arm of the DHH group (response rate 0% vs 17.4%,  $P = .033$ ) (Tables 2 and S3).

### 3.4 | Safety and treatment intensity in FOLFIRI and mXELIRI arms

The safety profiles of FOLFIRI and mXELIRI have been previously reported.<sup>14</sup> The most common grade 3-4 AEs of special interest in the FOLFIRI and mXELIRI arms were neutropenia (42.9% and 16.8%, respectively) and diarrhea (3.2% and 7.1%, respectively). Adverse events tended to be similar regardless of the *UGT1A1* genotype. Overall, grade 3-4 neutropenia was more common in the FOLFIRI arm than in the mXELIRI arm (35.9%, 50.4%, and 45.8% vs 17.0%, 15.7%, and 21.7%, respectively, in the WT, SH, and DHH groups) (Table 3). Grade 3-4 neutropenia was more likely to occur during the earlier cycles (up to #4) than during later cycles in both treatment groups. Especially with the FOLFIRI regimen, grade 3-4 neutropenia developed more frequently during the earlier cycles in the DHH group than in the WT and SH groups (Table S4). Grade 3-4 diarrhea was more common in the mXELIRI arm than the FOLFIRI arm (Table 3). Grade 3-4 neutropenia and diarrhea tended to be more common in patients with the *UGT1A1\*6* genotype than those with the *UGT1A1\*28* genotype (Table S5).

In the FOLFIRI arm, the relative dose intensity of irinotecan was lower in the DHH group (62.1%) than in the WT (74.6%) and SH (73.1%) groups. In the mXELIRI arm, the relative dose intensities of irinotecan were 85.7%, 84.6%, and 86.1% in the WT, SH, and DHH groups, respectively (Table 4). Discontinuation of study treatment for unacceptable toxicity was more common among DHH patients treated with FOLFIRI (16.7%)

**TABLE 1** Baseline characteristics of patients with metastatic colorectal cancer, grouped according to *UGT1A1* genotype (WT, single heterozygous [SH], or double heterozygous or homozygous [DHH])

	Patients, n (%)			<i>P</i> <sup>a</sup>
	WT (n = 309)	SH (n = 291)	DHH (n = 50)	
Age, median (range), y	60.0 (24-85)	61.0 (27-84)	62.0 (25-78)	.5303 <sup>b</sup>
Treatment arm				
FOLFIRI with or without BV	158 (51.1)	140 (48.1)	26 (52.0)	.7232
XELIRI with or without BV	151 (48.9)	151 (51.9)	24 (48.0)	
Sex				
Male	183 (59.2)	174 (59.8)	28 (56.0)	.8806
Female	126 (40.8)	117 (40.2)	22 (44.0)	
Country				
Korea	107 (34.6)	103 (35.4)	18 (36.0)	.9784
China	77 (24.9)	66 (22.7)	12 (24.0)	
Japan	125 (40.5)	122 (41.9)	20 (40.0)	
ECOG PS				
0-1	307 (99.4)	288 (99.0)	49 (98.0)	.6287
2	2 (0.6)	3 (1.0)	1 (2.0)	
Primary tumor location <sup>c</sup>				
Right side	78 (25.2) <sup>d</sup>	69 (24.2) <sup>e</sup>	17 (34.0)	
Left side	237 (76.7) <sup>d</sup>	221 (77.5) <sup>e</sup>	33 (66.0)	
No. of metastatic sites				
1	107 (34.6)	112 (38.5)	16 (32.0)	.5035
>1	202 (65.4)	179 (61.5)	34 (68.0)	
Adjuvant chemotherapy				
Yes	75 (24.3)	73 (25.1)	11 (22.0)	.8908
No	234 (75.7)	218 (74.9)	39 (78.0)	
Prior oxaliplatin				
Yes	300 (97.1)	285 (97.9)	49 (98.0)	.7789
No	9 (2.9)	6 (2.1)	1 (2.0)	
Prior anti-EGFR Ab therapy				
Yes	48 (15.5)	49 (16.8)	8 (16.0)	.9097
No	261 (84.5)	242 (83.2)	42 (84.0)	
Prior BV				
Yes	89 (28.8)	85 (29.2)	16 (32.0)	.8767
No	220 (71.2)	206 (70.8)	34 (68.0)	
Concomitant BV in this study				
Yes	256 (82.8)	243 (83.5)	42 (84.0)	.9659
No	53 (17.2)	48 (16.5)	8 (16.0)	
KRAS status				
WT	121 (39.2)	125 (43.0)	17 (34.0)	.4395
Mutant	101 (32.7)	77 (26.5)	16 (32.0)	
Unknown	87 (28.2)	89 (30.6)	17 (34.0)	


Abbreviations: BV, bevacizumab; EGFR, epidermal growth factor receptor; FOLFIRI, fluorouracil, leucovorin, plus irinotecan; PS, performance status; XELIRI, capecitabine plus irinotecan.

<sup>a</sup> $\chi^2$  test (except for <sup>b</sup>one-way ANOVA); comparing proportion of each characteristic.

<sup>c</sup>No comparison made because of duplicate aggregation.


<sup>d</sup>Total numbers do not match as six patients had duplicates for WT.

<sup>e</sup>Total numbers do not match as five patients had with duplicates for SH.



**FIGURE 2** Kaplan-Meier analysis of (A) progression-free survival and (B) overall survival in patients with metastatic colorectal cancer according to *UGT1A1* genotypes. CI, confidence interval; DHH, double heterozygous or homozygous; SH, single heterozygous





**FIGURE 3** Kaplan-Meier analysis of (A) progression-free survival and (B) overall survival in patients with metastatic colorectal cancer according to *UGT1A1* genotypes and treatment groups. CI, confidence interval; DHH, double heterozygous or homozygous; FOLFIRI, fluorouracil, leucovorin, plus irinotecan; SH, single heterozygous; mXELIRI, modified capecitabine plus irinotecan

**TABLE 2** Response rates in patients with metastatic colorectal cancer, grouped according to *UGT1A1* genotype (WT, single heterozygous [SH], or double heterozygous or homozygous [DHH]) and treatment (fluorouracil, leucovorin, plus irinotecan [FOLFIRI] or capecitabine plus irinotecan [XELIRI])

	Patients					
	WT		SH		DHH	
	FOLFIRI (n = 153)	mXELIRI (n = 147)	FOLFIRI (n = 133)	mXELIRI (n = 140)	FOLFIRI (n = 24)	mXELIRI (n = 23)
Complete response	2 (1.3)	8 (5.4)	0 (0.0)	5 (3.6)	0 (0.0)	0 (0.0)
Partial response	28 (18.3)	28 (19.0)	27 (20.3)	30 (21.4)	0 (0.0)	4 (17.4)
Stable disease	88 (57.5)	76 (51.7)	63 (47.4)	77 (55.0)	15 (62.5)	12 (52.2)
Progressive disease	29 (19.0)	26 (17.7)	32 (24.1)	18 (12.9)	6 (25.0)	6 (26.1)
Not evaluable	6 (3.9)	9 (6.1)	11 (8.3)	10 (7.1)	3 (12.5)	1 (4.3)
Objective response	30 (19.6)	36 (24.5)	27 (20.3)	35 (25.0)	0 (0.0)	4 (17.4)
	P = .308		P = .354		P = .033	

Note: Data are shown as n (%).

**TABLE 3** Grade 3 or 4 toxicities in the safety population of study patients with metastatic colorectal cancer, grouped according to *UGT1A1* genotype (WT, single heterozygous [SH], or double heterozygous or homozygous [DHH]) and treatment (fluorouracil, leucovorin, plus irinotecan [FOLFIRI] or modified capecitabine plus irinotecan [mXELIRI])

	FOLFIRI			mXELIRI		
	WT (n = 153)	SH (n = 133)	DHH (n = 24)	WT (n = 147)	SH (n = 140)	DHH (n = 23)
Any	73 (47.7)	78 (58.6)	15 (62.5)	49 (33.3)	47 (33.6)	9 (39.1)
Leucopenia	13 (8.5)	16 (12.0)	6 (25.0)	7 (4.8)	7 (5.0)	2 (8.7)
Neutropenia	55 (35.9)	67 (50.4)	11 (45.8)	25 (17.0)	22 (15.7)	5 (21.7)
Anemia	7 (4.6)	5 (3.8)	1 (4.2)	3 (2.0)	4 (2.9)	3 (13.0)
Thrombocytopenia	1 (0.7)	0 (0.0)	0 (0.0)	2 (1.4)	1 (0.7)	1 (4.3)
Febrile neutropenia	9 (5.9)	3 (2.3)	1 (4.2)	2 (1.4)	6 (4.3)	2 (8.7)
Nausea	4 (2.6)	3 (2.3)	2 (8.3)	4 (2.7)	6 (4.3)	3 (13.0)
Diarrhea	2 (1.3)	8 (6.0)	0 (0.0)	7 (4.8)	15 (10.7)	0 (0.0)
Mucositis	5 (3.3)	4 (3.0)	0 (0.0)	2 (1.4)	2 (1.4)	1 (4.3)
Fatigue	4 (2.6)	2 (1.5)	2 (8.3)	5 (3.4)	5 (3.6)	0 (0.0)
Hand-foot syndrome	1 (0.7)	0 (0.0)	0 (0.0)	3 (2.0)	2 (1.4)	1 (4.3)

Note: Data are shown as n (%).

when compared with mXELIRI (8.7%). After discontinuation of protocol treatment, third-line chemotherapy was given to 60.1% of WT patients in the FOLFIRI arm and 58.3% of WT patients in the mXELIRI arm. These values were 55.0% and 62.3% in the SH group, and 65.4% and 54.2% in the DHH group, for the FOLFIRI and mXELIRI arms, respectively.

## 4 | DISCUSSION

Here, we showed that mXELIRI with or without bevacizumab is non-inferior to FOLFIRI with or without bevacizumab in terms of OS, regardless of the *UGT1A1* genotype. No significant differences were found in the PFS and objective response between the treatment

groups regardless of *UGT1A1* genotypes. Adverse events such as neutropenia were less common in the mXELIRI arm than in the FOLFIRI arm across all *UGT1A1* genotypes. Our results suggest that mXELIRI with bevacizumab could become one of the standard treatments for colorectal cancer as a second-line treatment regardless of the *UGT1A1* genotype.

Another interesting finding from the current study is that patients with the DHH genotype had significantly worse OS than patients with WT or SH genotypes, especially in the FOLFIRI arm. The same trends were observed for objective response rate and PFS. This is in contrast to the results of the study by Toffoli et al,<sup>8</sup> which reported that FOLFIRI consisting of irinotecan 180 mg/m<sup>2</sup> as the first-line chemotherapy achieved a higher response rate (67%) in patients homozygous



**TABLE 4** Relative dose intensity in patients with metastatic colorectal cancer, grouped according to *UGT1A1* genotype and treatment regimen

	WT		SH			DHH				
	FOLFIRI, %	mXELIRI, %	FOLFIRI, %	<i>P</i> <sup>a</sup>	mXELIRI, %	<i>P</i> <sup>a</sup>	FOLFIRI, %	<i>P</i> <sup>a</sup>	mXELIRI, %	<i>P</i> <sup>a</sup>
Irinotecan	74.6	85.7	73.1	.749	84.6	.478	62.1	.143	86.1	.928
Capecitabine	–	85.7	–		85.5	.669	–		85.2	.632
5-FU bolus	89.8	–	87.8	.792	–		96.3	.752	–	
5-FU infusion	74.3	–	73.8	.922	–		62.2	.184	–	

Abbreviations: 5-FU, 5-fluorouracil; DHH, double heterozygote or homozygote; FOLFIRI, fluorouracil, leucovorin, plus irinotecan; SH, single heterozygote; XELIRI, capecitabine plus irinotecan.

<sup>a</sup>Wilcoxon rank sum test for the same WT and same arm. The italic values were no significant differences.

for *UGT1A1*\*28 than WT (40%) or SH (42%) patients. Such a difference in the efficacy is likely due to different ethnicity, as homozygosity for *UGT1A1*\*6 was observed exclusively in Asian populations and the frequency of *UGT1A1*\*6 is higher than *UGT1A1*\*28 in Asian populations.<sup>15,16</sup> Regarding the *UGT1A1*\*6 and \*28 alleles, our findings revealed that more patients with the *UGT1A1*\*6 genotype developed grade 3–4 neutropenia and diarrhea compared with patients carrying the *UGT1A1*\*28 genotype. A dose-finding study of irinotecan monotherapy with 150 mg/m<sup>2</sup> in Japanese patients with *UGT1A1* SH and/or DHH genotype showed dose reductions or delayed treatment in subsequent cycles because of grade 3 or 4 neutropenia.<sup>17</sup> In fact, compared with patients with other genotypes, DHH patients were more likely to develop grade 3–4 neutropenia during the early treatment cycles, more so especially in the FOLFIRI group than in the mXELIRI group. We considered the possibility that the inferior PFS for FOLFIRI compared with mXELIRI might reflect the higher rate of treatment discontinuation as a result of unacceptable toxicity associated with FOLFIRI. Therefore, FOLFIRI with irinotecan 150 mg/m<sup>2</sup> might have been overdosed in some cases in the DHH group.

Higher irinotecan dose intensity (86.1% vs 62.1%) and improved safety (grade 3 or higher toxicities, 39.1% vs 62.5%) were evident in the mXELIRI arm compared with the FOLFIRI arm in the DHH group. Efficacy as assessed by PFS and OS was better with the mXELIRI regimen than the FOLFIRI regimen in the DHH group (6.5 vs 4.8 months, and 13.0 vs 9.1 months, respectively); however, these differences were not statistically significant, which is probably due to the limited sample size. Although the superiority of mXELIRI could not be proven, the median PFS and OS were both longer in the mXELIRI group than in the FOLFIRI group by 1.7 months (HR 0.73; 95% CI, 0.41–1.32) and 3.9 months (HR 0.71; 95% CI, 0.39–1.31), respectively. These data suggest that mXELIRI can be given safely to patients with the DHH genotype while maintaining efficacy.

Our study has several limitations. First, because the concentration of drug in the blood was not quantified, we do not know whether the concentration of the active form of a poor metabolizer was increased in the blood, thereby leading to a higher efficacy due to greater SN-38 levels. Second, biases could have been present because the distribution of right-sided colon cancer, which is a prognostic factor in patients with colorectal cancer, was not adjusted in this study in order

to investigate the usefulness of *UGT1A1* genotyping. Third, the sample size might have been too small to rigorously compare the efficacy of mXELIRI- and FOLFIRI-based treatments in the DHH group. Finally, it is difficult to conclusively suggest an appropriate dose of irinotecan for FOLFIRI in the DHH group, although it might have been necessary to further reduce the starting dose to 120 mg/m<sup>2</sup> irinotecan, or to eliminate the bolus infusion of fluorouracil.

Although *UGT1A1* genotyping was mandatory in this study, it is not recommended in routine practice. Real-world data showed that the proportion of patients with DHH genotypes for *UGT1A1* was 7%–10% and that they did not tolerate the standard FOLFIRI regimen containing 180 mg/m<sup>2</sup> irinotecan.<sup>8</sup> Therefore, *UGT1A1* genotyping would be considered prior to treatment with FOLFIRI containing irinotecan 180 mg/m<sup>2</sup> when extra caution is required due to comorbidities or older age. Despite the establishment of some recommendations, routine upfront *UGT1A1* genotyping is not currently carried out. This could be because there have been few prospective studies that evaluated the clinical effects of genotype-directed dosing.<sup>18,19</sup> Other challenges for routine *UGT1A1* testing to avoid severe neutropenia include added costs and long turnaround time.

Precision medicine based on next-generation sequencing of tumor tissues is becoming a standard-of-care in mCRC and other cancers, and the costs thereof are covered by insurance in several countries such as the United States, Germany, Korea, and Japan. Recently, the MI-ONCOSEQ study produced reliable germline pharmacogenetics information on several clinically relevant pharmacogenes (eg, *TPMT*, *DYPD*, and *CYP2C19*).<sup>20</sup> Further updates on *UGT1A1* through prospective studies are needed. Integration of germline pharmacogenetics into tumor sequencing programs and the bioinformatics workflow will provide a unique opportunity to streamline and maximize the clinical benefit of genome testing without additional genotyping costs.

In conclusion, mXELIRI with or without bevacizumab as second-line chemotherapy for mCRC was efficacious and had an acceptable AE profile regardless of the *UGT1A1* genotype.

## ACKNOWLEDGMENTS

We thank the Scientific Publications Team and Joon Seo Lim at Asan Medical Center for their editorial assistance. This trial was sponsored by the Epidemiological and Clinical Research

Information Network (ECRIN: global sponsor), the Asan Medical Center Academic Research Office, and the Sun Yat-sen University Cancer Center, and was funded by Chugai Pharmaceutical and F Hoffmann-La Roche.

## DISCLOSURE

Satoru Iwasa reported receiving honoraria from Chugai and Taiho and research funding from Daiichi Sankyo and Pfizer. Kei Muro reported receiving honoraria from Chugai and Taiho and research funding from Daiichi Sankyo, Pfizer, and Taiho. Satoshi Morita reported receiving honoraria from Chugai, Pfizer, and Taiho. Masato Nakamura reported receiving honoraria from Chugai, Yakult Honsha, and Taiho. Masahito Kotaka reported receiving honoraria from Chugai and Yakult Honsha. Tomohiro Nishina reported receiving honoraria from Chugai and Taiho and research funding from Chugai, Daiichi Sankyo, and Taiho. Keun-Wook Lee reported receiving honoraria from Genexine, MedPacto, and ISU abxis. Yasuhide Yamada reported receiving honoraria from Chugai, Nipponkayaku, and Taiho and grants from Daiichi Sankyo. Junichi Sakamoto reported receiving an honorarium from Chugai. The other authors have no conflicts of interest to declare.

## ORCID

Satoru Iwasa  <https://orcid.org/0000-0003-3863-9582>

Sang-Hee Cho  <https://orcid.org/0000-0002-7995-7862>

Wei-Jia Fang  <https://orcid.org/0000-0001-9849-347X>

## REFERENCES

1. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol*. 2004;22:229-237.
2. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. *JAMA*. 2017;317:2392-2401.
3. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. *Lancet Oncol*. 2013;14:29-37.
4. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol*. 2015;16:499-508.
5. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol*. 2012;30:3499-3506.
6. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol*. 2010;28:4706-4713.
7. Iyer L, King CD, Whittington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. *J Clin Invest*. 1998;101:847-854.
8. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1\*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. *J Clin Oncol*. 2006;24:3061-3068.
9. Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. *J Clin Oncol*. 2009;27:2457-2465.
10. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. *J Clin Oncol*. 2006;24:2237-2244.
11. Martínez-Balbrea E, Abad A, Martínez-Cardús A, et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. *Br J Cancer*. 2010;103:581-589.
12. Côté JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. *Clin Cancer Res*. 2007;13:3269-3275.
13. Wang Y, Shen L, Xu N, et al. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. *World J Gastroenterol*. 2012;18:6635-6644.
14. Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. *Lancet Oncol*. 2018;19:660-671.
15. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. *J Clin Oncol*. 2009;27:2604-2614.
16. Maeda H, Hazama S, Shavkat A, et al. Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations. *Mol Diagn Ther*. 2014;18:333-342.
17. Satoh T, Ura T, Yamada Y, et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1\*28 and/or UGT1A1\*6 polymorphisms. *Cancer Sci*. 2011;102:1868-1873.
18. Quaranta S, Thomas F. Pharmacogenetics of anti-cancer drugs: State of the art and implementation – recommendations of the French National Network of Pharmacogenetics. *Therapie*. 2017;72:205-215.
19. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working group: recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? *Genet Med*. 2009;11:15-20.
20. Hertz DL, Glatz A, Pasternak AL, et al. Integration of germline pharmacogenetics into a tumor sequencing program. *JCO Precis Oncol*. 2018;2(2):1-15.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Iwasa S, Muro K, Morita S, et al. Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. *Cancer Sci*. 2021;112:4669–4678. <https://doi.org/10.1111/cas.15092>